Assessment of diagnostic enzyme-linked immunosorbent assay kit and serological markers in human brucellosis

Japanese Journal of Infectious Diseases

Volumn 61, Issue 5, 2008, Pages 366-370

  Cakan, Gulcin ^a   Bezirci, Fatma Betul ^a   Kacka, Askin ^b   Cesur, Salih ^c   Aksaray, Sebahat ^d   Tezeren, Deniz ^d   Saka, Dilek ^e   Ahmed, Kamruddin ^a,f  

^a BILKENT UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c Refik Saydam Hygiene Center   (Turkey)

^d ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e Ataturk Chest Disease and Chest Surgery Center   (Turkey)

^f OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEOPTERIN; ROSE BENGAL; BACTERIUM ANTIBODY; IMMUNOGLOBULIN;

ADULT; AGGLUTINATION TEST; ARTICLE; BLOOD SAMPLING; BRUCELLA; BRUCELLOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; ADOLESCENT; ANALYTICAL EQUIPMENT; BLOOD; EVALUATION; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, CD14; BRUCELLA; BRUCELLOSIS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPROTEINS; MALE; MIDDLE AGED; NEOPTERIN; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 54449100503     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Atmaca, S., Ozekinci, T., Akpolat, N., et al. (2004): Brucellosis seroprevalence in Southeast Turkey. Turk. J. Med. Sci., 34, 251-255.
2. Karabay, O., Sencan, I., Kayas, D., et al. (2004): Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTNI 1871179]. BMC Infect. Dis., 4,18.
3. Mert, A., Ozaras, R., Tabak, F., et al. (2003): The sensitivity and specificity of Brucella agglutination tests. Diag. Microbiol. Infect. Dis., 46, 241-243.
4. Ariza, J., Pellicer, T., Pallares, R., et al. (1992): Specific antibody profile in human brucellosis. Clin. Infect. Dis., 12, 131-140.
5. Dicz-Ruiz, A., al-Amrani, M., Weiss, G., et al. (1993): Increased interferon-gamma and neopterin concentrations in patients with acute brucellosis. J. Infect. Dis., 167, 504-505.
6. Ahmed, K., Al-Matrouk, K.A., Martinez, G., et al. (1999): Increased serum levels of interferon-γ and interleukin-12 during human brucellosis. Am. J. Trop. Med. Hyg., 61, 425-427.
7. Huber, C.,, Batchelor, J.R., Fuchs, D., et al. (1984): Immune responseassociated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J. Exp. Med., 160, 310-316.
8. Shi, M., Taylor, J.M., Fahey, J.L., et al. (1997): Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression. J. Clin. Inummol., 17, 43-52.
9. Millner, M.M., Franthal, W., Thalhammer, G.H., et al. (1998): Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children. Clin. Chem., 44, 161-167.
10. Berdowska, A. and Zwirska-Korczala, K. (2001): Neopterin measurement in clinical dignosis. J. Clin. Pharm. Ther., 26, 319-329.
11. Mitaka, C. (2005): Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin. Chem. Acta, 351, 17-29.
12. Bass, S., Gauthier, B.R., Spenato, U., et al. (2004): CD14 is an acutephase protein. J. Inummol., 172, 4470-4479.
13. Guyatt, G., Sackett, D. and Haynes, B. (2006): Evaluating diagnostic tests. p. 273-322. In R.B. Haynes, D.L. Sackett, G.H. Guyatt, et al. (ed.), Clinical Epidemiology: How To Do Clinical Practice Research. Lippincott Williams & Wilkins, Pa., USA.
14. Araj, G.F., Kattar, M.M., Fattouh, L.G., et al. (2005): Evaluation of the PANBIO brucella immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assay for diagnosis of human brucellosis. Clin. Diag. Lab. Inummol., 12, 1334-1335.
15. Memish, Z.A., Almuneef, M., Mah, M.W., et al. (2002): Comparison of the Brucella standard agglutination test with the ELISA IgG and IgM in patients with Brucella bacteremia. Diag. Microbiol. Infect. Dis., 44, 129-132.
16. Gazapo, E., Lahoz, J.G., Subiza, J.L., et al. (1989): Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow-up. J. Infect. Dis., 159, 219-225.
17. Al Dahouk, S., Tomaso, H., Nockler, K., et al. (2003): Laboratory-based diagnosis of brucellosis-a review of the literature, part II: scrological tests for brucellosis. Clin. Lab., 49, 577-589.
18. Navarro, J.M. (1990): C-reactive protein as a prognostic indicator in acute brucellosis. Diagn. Microbiol. Infect. Dis., 13, 269-270.
19. Ayaslioglu, E., Tekeli, E. and Birengel, S. (2005): Significant elevation of serum soluble CD14 levels in patients with brucellosis. Jpn. J. Infect. Dis., 58, 11-14.
20. Arias, M.A., Rey Nores, J.E., Vita, N., et al. (2000): Cutting edge: human B cell function is regulated by interaction with soluble CD1,4: opposite effects on IgG1 and IgE production. J. Immunol,, 164, 3480-3486.
21. Rey-Nores, J.E., Bensussan, A, Vita, N., et al. (1999): Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur. J. Immunol., 29, 265-276.
22. Saltoglu, N., Tasova, Y., Midikli, D., et al. (2004): Fever of unknown origin in Turkey: evaluation of 87 cases during a nine-year-period of study. J. Infect., 48, 81-85.
23. Ergonul, O., Willke, A., Azap, A., et al. (2005): Revised definition of 'fever of unknown origin': limitations and opportunities. J. Infect., 50, 1-5.